Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CDC42 | P60953 | 1/20 | 0.58 |
| ▸ | RAC1 | P63000 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9652335 | 1.00 | TDP1 (0.61) | TDP1L3MBTL1PTGS2PTGS1AKR1C3 | |
| Tetrahydrofuran SCHEMBL11025631 | 0.92 | TDP1 (0.53) | TDP1L3MBTL1PTGS2PTGS1AKR1C3 | |
| SCHEMBL18117653 | 0.87 | TDP1 (0.53) | TDP1L3MBTL1PTGS2PTGS1AKR1C3 | |
| SCHEMBL12344526 | 0.87 | TDP1 (0.59) | TDP1L3MBTL1PTGS2PTGS1AKR1C3 | |
| SCHEMBL23647290 | 0.87 | TDP1 (0.59) | TDP1L3MBTL1PTGS2PTGS1AKR1C3 | |
| SCHEMBL23664384 | 0.86 | TDP1 (0.52) | TDP1L3MBTL1PTGS2PTGS1AKR1C3 | |
| SCHEMBL22932278 | 0.86 | TDP1 (0.43) | TDP1L3MBTL1PTGS2PTGS1AKR1C3 | |
| SCHEMBL219579 | 0.82 | TDP1 (0.59) | TDP1L3MBTL1PTGS2PTGS1AKR1C3 | |
| SCHEMBL23969668 | 0.82 | TDP1 (0.59) | TDP1L3MBTL1PTGS2PTGS1AKR1C3 | |
| SCHEMBL22651683 | 0.82 | AKR1C3 (0.58) | TDP1L3MBTL1PTGS2PTGS1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207423-A1 | PROGAMMABLE POLYMERIC DRUGS | SONY GROUP CORP (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240207423-A1 | PROGAMMABLE POLYMERIC DRUGS | SONY GROUP CORP (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-3737418-B1 | POLYMERS WITH RIGID SPACING GROUPS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | SONY GROUP CORP (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-11312736-B1 | Programmable polymeric drugs | SONY CORPORATION (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20210128739-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2021-05-06 | — | — | US | disclosed |
| US-20210128591-A1 | IONIC POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | SONY CORPORATION (JP) | 2021-05-06 | — | — | US | disclosed |
| US-20210032277-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2021-02-04 | — | — | US | disclosed |
| US-20200360526-A1 | PHOSPHOALKYL POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | Sony Group Corporation (JP) | 2020-11-19 | — | — | US | disclosed |
| US-20200353094-A1 | PHOSPHOALKYL RIBOSE POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | Sony Group Corporation (JP) | 2020-11-12 | — | — | US | disclosed |
| US-20200353089-A1 | POLYMERS WITH RIGID SPACING GROUPS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | Sony Group Corporation (JP) | 2020-11-12 | — | — | US | disclosed |
| US-7615618-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| EP-1789553-A2 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | Alnylam Pharmaceuticals Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1768998-A2 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A 2-ARYLPROPYL MOIETY | Alnylam Pharmaceuticals Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060287260-A1 | Ribonucleoside substituted with a phosphonamidite group at the 3'-position; the phosphonamidite may be an alkyl phosphonamidite; can be used to prepare oligonucleotides used in gene therapy; improved serum solubility, cellular distribution and uptake, and stability in vivo | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2006088490-A2 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006078278-A2 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A 2-ARYLPROPYL MOIETY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060008822-A1 | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-01-12 | — | — | US | disclosed |
| EP-0331471-B1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTIINFLAMMATORY DRUGS | Larsen, Claus Selch (DK) | 1992-12-16 | — | — | EP | disclosed |
| WO-1989008119-A1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTI-INFLAMMATORY DRUGS | SELCH LARSEN CLAUS (DK) | 1989-09-08 | — | — | WO | disclosed |
| EP-0331471-A1 | High molecular weight prodrug derivatives of antiinflammatory drugs | Larsen, Claus Selch (DK) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312736-B1 | Programmable polymeric drugs | NCL, PBRM1, LPXN | TDP1 623/4885L3MBTL1 81/4885PTGS2 3678/4885 |
| US-20060008822-A1 | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety | P2RY2, DERA, P2RY6 | TDP1 946/4885L3MBTL1 1834/4885PTGS2 354/4885 |
| US-20210128739-A1 | PROGRAMMABLE POLYMERIC DRUGS | CHRM1, PBRM1, MRPL21 | TDP1 667/4885L3MBTL1 11/4885PTGS2 3654/4885 |
| US-20060287260-A1 | Ribonucleoside substituted with a phosphonamidite group at the 3'-position; the phosphonamidite may be an alkyl phosphonamidite; can be used to prepare oligonucleotides used in gene therapy; improved serum solubility, cellular distribution and uptake, and stability in vivo | PNP, RNMT, SLC29A2 | TDP1 784/4885L3MBTL1 358/4885PTGS2 4442/4885 |
| US-20200353094-A1 | PHOSPHOALKYL RIBOSE POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | PARP1, PARP11, PHOSPHO1 | TDP1 216/4885L3MBTL1 68/4885PTGS2 4298/4885 |
| US-20210032277-A1 | PROGRAMMABLE POLYMERIC DRUGS | NCL, PBRM1, LPXN | TDP1 623/4885L3MBTL1 81/4885PTGS2 3678/4885 |
| US-20200353089-A1 | POLYMERS WITH RIGID SPACING GROUPS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | MRPL21, TLN1, L3MBTL1 | TDP1 711/4885L3MBTL1 3/4885PTGS2 3413/4885 |
| US-20200360526-A1 | PHOSPHOALKYL POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | PHOSPHO1, PGM2, PHYKPL | TDP1 879/4885L3MBTL1 28/4885PTGS2 3709/4885 |
| US-20240207423-A1 | PROGAMMABLE POLYMERIC DRUGS | OPRM1, CHRM1, TUBB3 | TDP1 3696/4885L3MBTL1 444/4885PTGS2 1424/4885 |
| US-20210128591-A1 | IONIC POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | TLN1, MRPL21, TLL1 | TDP1 569/4885L3MBTL1 7/4885PTGS2 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.